HR 3240
106th Congress
House
Health
Commerce
Drug adulteration
Drug approvals
Drug industry
Drugs
Foreign Trade and International Finance
Government Operations and Politics
Government paperwork
Government publicity
Import restrictions
Imports
Labeling
Pharmacists
Drug Import Fairness Act of 1999
Introduced: November 5, 1999
See on congress.gov
Everywhere this bill has been
13 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 29, 2000
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H5426-5427)
Jun 29, 2000
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jun 29, 2000
Motion to reconsider laid on the table Agreed to without objection.
Jun 29, 2000
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5426-5427)
Jun 28, 2000
DEBATE - The House proceeded with forty minutes of debate on H.R. 3240.
Jun 28, 2000
DEBATE - The House resumed debate on H.R. 3240.
Jun 28, 2000
Considered under suspension of the rules. (consideration: CR H5426-5434)
Jun 28, 2000
Mr. Bilbray moved to suspend the rules and pass the bill.
Apr 11, 2000
Sponsor introductory remarks on measure. (CR H2096-2097)
Feb 14, 2000
Sponsor introductory remarks on measure. (CR H360-361)
Nov 17, 1999
Referred to the Subcommittee on Health and Environment.
Nov 5, 1999
Referred to the House Committee on Commerce.
Nov 5, 1999
Introduced in House
Plain-English summary
Drug Import Fairness Act of 1999 - Amends the Federal Food, Drug, and Cosmetic Act (FDCA) to prohibit the Secretary of Health and Human Services, with regard to a drug being imported or offered for import, from sending a notice to a person suggesting that importing the drug is, or appears to be, in violation of the FDCA unless: (1) the Secretary determines the drug is adulterated, misbranded, in violation of FDCA provisions relating to new drugs, the drug is forbidden or restricted in sale in the producing or exporting country, importation by any person other than the manufacturer violates reimportation provisions, or the importation otherwise violates Federal law; (2) the notice does not specify any provision described in the provisions of this act relating to those determinations that is not applicable to the drug's importation; and (3) the notice states the underlying reasons for the determination.
What's happening now
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
3
Cosponsors
1